Sahm D F, Karlowsky J A, Kelly L J, Critchley I A, Jones M E, Thornsberry C, Mauriz Y, Kahn J
MRL, Herndon, Virginia 20171-4603, USA.
Antimicrob Agents Chemother. 2001 Apr;45(4):1037-42. doi: 10.1128/AAC.45.4.1037-1042.2001.
Although changing patterns in antimicrobial resistance in Streptococcus pneumoniae have prompted several surveillance initiatives in recent years, the frequency with which these studies are needed has not been addressed. To approach this issue, the extent to which resistance patterns change over a 1-year period was examined. In this study we analyzed S. pneumoniae antimicrobial susceptibility results produced in our laboratory with isolates obtained over 2 consecutive years (1997-1998 and 1998-1999) from the same 96 institutions distributed throughout the United States. Comparison of results revealed increases in resistant percentages for all antimicrobial agents studied except vancomycin. For four of the agents tested (penicillin, cefuroxime, trimethoprim-sulfamethoxazole, and levofloxacin), the increases were statistically significant (P < 0.05). Resistance to the fluoroquinolone remained low in both years (0.1 and 0.6%, respectively); in contrast, resistance to macrolides was consistently greater than 20%, and resistance to trimethoprim-sulfamethoxazole increased from 13.3 to 27.3%. Multidrug resistance, concurrent resistance to three or more antimicrobials of different chemical classes, also increased significantly between years, from 5.9 to 11%. The most prevalent phenotype was resistance to penicillin, azithromycin (representative macrolide), and trimethoprim-sulfamethoxazole. Multidrug-resistant phenotypes that included fluoroquinolone resistance were uncommon; however, two phenotypes that included fluoroquinolone resistance not found in 1997-1998 were encountered in 1998-1999. This longitudinal surveillance study of resistance in S. pneumoniae revealed that significant changes do occur in just a single year and supports the need for surveillance at least on an annual basis, if not continuously.
尽管近年来肺炎链球菌抗菌药物耐药模式的变化促使开展了多项监测工作,但尚未明确这些研究的开展频率。为解决这一问题,我们研究了耐药模式在1年时间内的变化程度。在本研究中,我们分析了本实验室对来自美国各地96家相同机构连续两年(1997 - 1998年和1998 - 1999年)分离的肺炎链球菌进行抗菌药物敏感性试验的结果。结果比较显示,除万古霉素外,所有研究的抗菌药物耐药百分比均有所增加。对于所测试的四种药物(青霉素、头孢呋辛、甲氧苄啶 - 磺胺甲恶唑和左氧氟沙星),耐药性增加具有统计学意义(P < 0.05)。两年中对氟喹诺酮类药物的耐药率均较低(分别为0.1%和0.6%);相比之下,对大环内酯类药物的耐药率始终高于20%,对甲氧苄啶 - 磺胺甲恶唑的耐药率从13.3%增至27.3%。耐多药,即同时对三种或更多不同化学类别的抗菌药物耐药,在两年间也显著增加,从5.9%增至11%。最常见的表型是对青霉素、阿奇霉素(代表性大环内酯类药物)和甲氧苄啶 - 磺胺甲恶唑耐药。包含氟喹诺酮耐药的耐多药表型并不常见;然而,在1998 - 1999年发现了1997 - 1998年未出现的两种包含氟喹诺酮耐药的表型。这项肺炎链球菌耐药性的纵向监测研究表明,仅在1年内就确实发生了显著变化,支持至少每年进行一次监测(即便不是持续监测)的必要性。